Melatonin Deficiency: Its Role in Oncogenesis and Age-related Pathology

John M. Fontenot, B.A.¹ and Stephen A. Levine, Ph.D.²

Summary

Melatonin deficiency may be a critical starting point for the degenerative processes leading to cellular pathology and oncogenesis. Relative melatonin deficiency at the cellular level may be induced by pineal gland decline and/or oxidative damage to melatonin receptor sites. Melatonin, as the primary neurohormone regulator, governs cellular metabolic processes via moderation of cellular cGMP and cAMP ratios, which control the production of intracellular antioxidants. Melatonin deficiency results in uncontrolled cAMP synthesis, leading to unregulated oxidative processes and subsequent free radical damage. Free radical induced pathology is a fundamental mediator of metabolic dysregulation underlying the development of pathological aging symptoms and the development of cancer. Exogenous melatonin has proved to arrest and reverse the consequences of its deficiency.

All processes can be described as the oscillatory balance of two principles. These principles can be fundamentally characterized by two basic forces of nature, homotropy (entropy) and heterotropy (preservation of order). This concept of dualism can be of great importance in the study of biological phenomena. There are two basic divisions of physiological processes; catabolism (homotropy) predominates during the day and is involved with the oxidative processes of energy production and immunity. During the day, energy production and immunity are regulated by hormones and enzymes which are replenished in a circadian fashion. Anabolic processes (heterotropy) predominate at night. Heterotropic forces direct organization and synthesis. It is in this phase that tissues are regenerated, hormones, enzymes and anti-

¹ & ² Allergy Research Group, 400 Preda Street, San Leandro, CA 94577.
Melatonin Deficiency: Its Role in Oncogenesis and Age-Related Pathology

degradation systems and antioxidant synthesis (Rozencwaig, 1987). It is the mean level of antioxidants that governs the function and longevity of the cell and thus the life span potential of the organism (Cutler, 1984).

Melatonin levels in animals and humans show age-dependent declines (Nair, 1986; Rozencwaig, 1987). Reduced melatonin levels result in a decline in protective and restorative processes and subsequently, a diminished responsiveness of the circadian systems to exogenous and endogenous stimuli (Moor-Ede, 1982). A reduced adaptive capacity may initiate the metabolic dysregulation leading to age-related pathology. The subsequent neuroendocrine changes induce the pathological changes observed in the aging organism: arteriosclerotic changes; free radical damage to membranes, resulting in reduced absorption of nutrients and excretion of waste products; hormonal changes mediated by a dysregulated hypothalamus-pituitary axis; changes in sleep patterns; increased incidence of cancer, etc.

Oral melatonin, administered to animals and humans, restored these adaptive systems (Arzt, 1988; Pierpaoli, 1987). The oncostatic and anti-proliferative effects of melatonin have been well-established (Barni, 1988; Esposti, 1988; Hill, 1988; Regelson, 1987). Treatment with melatonin has been reported to inhibit the growth of specific cancer cells (Tamarkin, 1981) and to inhibit the induction of tumors by carcinogenic agents (Quay, 1980). Both high and low melatonin blood levels have been observed in neoplastic disorders (Lissoni, 1986; Pico, 1979). We suspect that in the early course of neoplastic development, high melatonin blood levels are seen because melatonin can not bind to free-radical damaged receptors. There is a functional melatonin deficiency at the cellular level in spite of high melatonin blood levels. As the cancer progresses, melatonin production may decline due to a lack of regulatory feedback from damaged cells.

Experiments have shown that exogenous melatonin has a therapeutic regulatory effect on the immune system (Maestroni, 1983). Melatonin, administered to mice completely negated the psychogenic stress effects produced by restraint and restored thymus weight. Melatonin was able to counter in vivo the suppression of antibody production produced by administration of corticosteroids (Pierpaoli, 1987). Melatonin protected stressed mice from exposure to encephalomyocarditis virus (EMV), a lethal neurotropic murine pathogen (Pierpaoli, 1987). Most of the mice which had been stressed and infected with EMV died, while most of the stressed melatonin-treated mice survived the virus. Exogenous melatonin may be indicated as an immunoprotective agent in conditions of environmental or psychogenic stress which promotes onset and development of infectious diseases, including AIDS. The immunoenhancement, anti-stress, and oncostatic effects of melatonin were blocked by the specific opioid antagonist naltrexone, indicating that melatonin acts via the endogenous opioid system (Maestroni, 1987).

Melatonin has demonstrated remarkable anti-aging effects in mice (Pierpaoli, 1987). Small doses, prolonged their lives by 20%. Not only were the lives of the treated animals extended but Pierpaoli writes, "melatonin exerted an extraordinary positive action on their performance and reversed or delayed the symptoms of age-related debility, disease, and cosmetic decline in a dramatic fashion."

Conclusion:

It is likely that the metabolic dysregulation leading to the development of the pathological symptoms often seen with the aging process and the onset of cancer are often initiated by a decline in melatonin production and/or utilization. These biochemical disorders originate in the disruption of those neuroendocrine adaptive feed-back process which are governed by melatonin. Melatonin's very low toxicity (Wurtman, 1985; Sugden, 1983) and the ample documentation of its therapeutic effects, call for further investigation.

References:


